Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 462

1.

Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.

Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.

JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1164-70. doi: 10.1001/jamaoto.2013.4501.

PMID:
24030686
2.

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.

World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.

PMID:
22190222
3.

The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Paulson L, Shindo M, Schuff K, Corless C.

Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):44-9. doi: 10.1001/archoto.2011.226.

PMID:
22249628
4.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10. Epub 2012 Mar 17.

PMID:
22426956
5.

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.

Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.

Biomed Pharmacother. 2014 May;68(4):413-7. doi: 10.1016/j.biopha.2014.03.008. Epub 2014 Mar 18.

PMID:
24721322
6.

The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.

Kurt B, Yalçın S, Alagöz E, Karslıoğlu Y, Yigit N, Günal A, Deveci MS.

Endocr Pathol. 2012 Sep;23(3):135-40. doi: 10.1007/s12022-012-9218-7.

PMID:
22767446
7.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V.

JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.

8.

BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.

Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG.

Endocr Pathol. 2012 Jun;23(2):83-93. doi: 10.1007/s12022-011-9184-5.

PMID:
22105775
9.

In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.

Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.

Clin Endocrinol (Oxf). 2012 Nov;77(5):780-6. doi: 10.1111/j.1365-2265.2012.04465.x.

PMID:
22702340
10.

BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.

Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY.

Auris Nasus Larynx. 2012 Apr;39(2):198-203. doi: 10.1016/j.anl.2011.07.011. Epub 2011 Aug 20.

PMID:
21862261
11.
12.

Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.

Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY.

Thyroid. 2013 Nov;23(11):1423-30. doi: 10.1089/thy.2013.0036. Epub 2013 Sep 27.

PMID:
23496275
13.

BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?

Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A.

World J Surg. 2014 Mar;38(3):679-87. doi: 10.1007/s00268-013-2223-2.

PMID:
24052184
14.

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.

Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5. Epub 2011 May 19.

PMID:
21594703
15.

Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.

Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC.

Med Oncol. 2012 Dec;29(5):3360-6. doi: 10.1007/s12032-012-0315-8. Epub 2012 Aug 2.

PMID:
22855362
16.

[Expression of BRAF V600E mutation in different thyroid lesions].

Wang W, Li XH, Zhang YH, Li J, Chen J, Zhao P, Li QY, Xiang JJ, Li X, Xu RJ.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):354-7. Chinese.

PMID:
21875464
17.

Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.

Kim BH, Kim IJ, Lee BJ, Lee JC, Kim IS, Kim SJ, Kim WJ, Jeon YK, Kim SS, Kim YK.

Yonsei Med J. 2015 May;56(3):634-40. doi: 10.3349/ymj.2015.56.3.634.

18.

The association between BRAF (V600E) mutation and pathological features in PTC.

Liu X, Yan K, Lin X, Zhao L, An W, Wang C, Liu X.

Eur Arch Otorhinolaryngol. 2014 Nov;271(11):3041-52. doi: 10.1007/s00405-013-2872-7. Epub 2014 Jan 4. Review.

PMID:
24389984
19.

Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?

Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS.

Am J Surg. 2012 Apr;203(4):436-41. doi: 10.1016/j.amjsurg.2011.02.013. Epub 2011 Jul 30.

PMID:
21803329
20.

Clinical significance of BRAF mutation in thyroid papillary cancer.

Fernandez IJ, Piccin O, Sciascia S, Cavicchi O, Repaci A, Vicennati V, Fiorentino M.

Otolaryngol Head Neck Surg. 2013 Jun;148(6):919-25. doi: 10.1177/0194599813481942. Epub 2013 Mar 12.

PMID:
23482475

Supplemental Content

Support Center